Loading candles…
Neuland Laboratories Limited operates in the pharmaceutical and chemical industries, specializing in the development and manufacture of Active Pharmaceutical Ingredients (APIs) as well as providing Contract Development and Manufacturing Organization (CDMO) services. The company serves both domestic and international markets, distributing products in over 80 countries. Its business segments include Generic APIs (GDS) and Custom Manufacturing Solutions (CMS). Neuland Laboratories offers end-to-end solutions that span from pre-investigational new drug (pre-IND) stages through commercial supply. The company emphasizes adherence to high-quality standards and regulatory compliance across a range of therapeutic areas. No information is provided regarding the company's year of incorporation, founders, key management, subsidiaries, or stock exchange listings.
| Date |
|---|
| Audited Results - Q4 & FY26 | Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial… | 12 May 2026 |
| Unaudited Results - Q3-FY25 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2025 | 9 Feb 2026 |
| Results - Q2 & FY25 | To consider and approve the financial results for the quarter and half year ended September 30, 2025 | 7 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 31 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 15 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.